LAUSR

16% vs. 61% patients had local vs. retroperitoneal vs. distant recurrences at first presentation. The 8-year CSM-free survival rates were 66 vs. 51 vs. 34% for patients with local vs. retroperitoneal vs. distant CR. At 8-year, 25 and 7% patients experienced CSM and OCM. Pathologic grade group 4-5 and seminal vesicle invasion (SVI) were associated with distant CR (all P 0.04). The risk of dying from OCM was the same as CSM in those with pathologic grade group 1-3 and no SVI at final pathology (4 vs. 0%). Conversely, 30 vs. 9% patients died from PCa vs. OCM among men with a pathologic grade group 4-5 or SVI. CONCLUSIONS: Up to 25% patients with lymphadenopathies treated with RP experience CR in the prostatic fossa or pelvic nodes. These individuals harbour more favourable outcomes as compared to those with retroperitoneal or distant metastases. Men with a grade group 1-3 and no SVI are at substantially higher risk of dying from other causes than the disease itself.